» Articles » PMID: 21626458

Corporate Social Responsibility for Nanotechnology Oversight

Overview
Specialty Medical Ethics
Date 2011 Jun 1
PMID 21626458
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Growing public concern and uncertainties surrounding emerging technologies suggest the need for socially-responsible behavior of companies in the development and implementation of oversight systems for them. In this paper, we argue that corporate social responsibility (CSR) is an important aspect of nanotechnology oversight given the role of trust in shaping public attitudes about nanotechnology and the lack of data about the health and environmental risks of nanoproducts. We argue that CSR is strengthened by the adoption of stakeholder-driven models and attention to moral principles in policies and programs. In this context, we examine drivers of CSR, contextual and leadership factors that influence CSR, and strategies for CSR. To illustrate these concepts, we discuss existing cases of CSR-like behavior in nanotechnology companies, and then provide examples of how companies producing nanomedicines can exhibit morally-driven CSR behavior.

Citing Articles

From Nano Backlash to Public Indifference: Some Reflections on French Public Dialogues on Nanotechnology.

Bensaude-Vincent B Nanoethics. 2021; 15(2):191-201.

PMID: 34512813 PMC: 8419674. DOI: 10.1007/s11569-021-00396-6.


Artificial intelligence and robotisation in the EU - should we change OHS law?.

Jarota M J Occup Med Toxicol. 2021; 16(1):18.

PMID: 33952297 PMC: 8097897. DOI: 10.1186/s12995-021-00301-7.

References
1.
Kuzma J, Romanchek J, Kokotovich A . Upstream oversight assessment for agrifood nanotechnology: a case studies approach. Risk Anal. 2008; 28(4):1081-98. DOI: 10.1111/j.1539-6924.2008.01071.x. View

2.
Kuzma J, Paradise J, Ramachandran G, Kim J, Kokotovich A, Wolf S . An integrated approach to oversight assessment for emerging technologies. Risk Anal. 2008; 28(5):1197-220. DOI: 10.1111/j.1539-6924.2008.01086.x. View

3.
Lenk C, Biller-Andorno N . Nanomedicine-emerging or re-emerging ethical issues? A discussion of four ethical themes. Med Health Care Philos. 2006; 10(2):173-84. DOI: 10.1007/s11019-006-9014-6. View

4.
Zadek S . The path to corporate responsibility. Harv Bus Rev. 2004; 82(12):125-32, 150. View

5.
Kuzma J, Najmaie P, Larson J . Evaluating oversight systems for emerging technologies: a case study of genetically engineered organisms. J Law Med Ethics. 2010; 37(4):546-86. DOI: 10.1111/j.1748-720X.2009.00431.x. View